In Vivo Model Development for Severe Combined Immunodeficiency Disease
Protheragen offers comprehensive in vivo model development services for Severe Combined Immunodeficiency Disease (SCID), supporting preclinical research and therapeutic evaluation. Our expertise in animal modeling ensures precise recapitulation of SCID pathophysiology, enabling clients to accelerate the discovery and validation of novel treatments.
Severe Combined Immunodeficiency Disease is a group of rare, inherited disorders characterized by profound defects in both humoral and cellular immunity. Accurate animal models are essential for elucidating disease mechanisms and evaluating the efficacy of gene, cell, and pharmacological therapies. Protheragen utilizes a range of species, including mice (notably the C.B-17 scid, NOD-scid, and NSG strains), rats, and occasionally larger mammals, to mirror the human SCID phenotype. These models are genetically or otherwise engineered to reflect the immunological deficiencies seen in patients, providing a robust platform for translational research.
Genetic SCID models are established by introducing targeted mutations into genes critical for immune function, such as Prkdc, IL2rg, or RAG1/2. The most commonly used are the C.B-17 scid, NOD-scid, and NSG (NOD scid gamma) mice, which lack mature T and B lymphocytes (and, in some cases, NK cells). These models closely mimic the genetic and immunological defects found in human SCID, making them highly predictive for translational research. Advantages include stable, reproducible immunodeficiency, suitability for xenotransplantation studies, and the ability to assess gene and cell therapy approaches. Primary applications include testing hematopoietic stem cell transplantation, gene editing strategies, and immune reconstitution therapies.
Chemically-induced SCID models are generated by administering agents such as cyclophosphamide, busulfan, or irradiation to selectively ablate immune cells in immunocompetent animals. This transiently induces an immunodeficient state resembling SCID, facilitating the study of immune system reconstitution and the engraftment of human cells or tissues. Key advantages include rapid model generation, flexibility in timing, and cost-effectiveness. These models are primarily used for short-term studies of immune recovery, drug screening, and evaluating the safety and efficacy of transplantation protocols.
Humanized SCID models involve engrafting immunodeficient mice (such as NSG or NOG strains) with human hematopoietic stem cells or peripheral blood mononuclear cells. This approach reconstitutes a functional human immune system within the animal, allowing for the study of human-specific immune responses and disease mechanisms. The main advantages are the ability to evaluate human immune cell development, function, and therapeutic interventions in a controlled in vivo environment. Applications include testing gene therapies, immunomodulatory drugs, and infectious disease susceptibility in a human-relevant context.
Protheragen delivers an end-to-end solution for SCID animal model development, from model selection and customization to experimental execution and data analysis. Our services include genetic engineering, chemical induction protocols, humanization procedures, and tailored study designs to meet specific research objectives. Key efficacy endpoints include immune cell profiling (flow cytometry for T, B, and NK cells), immunoglobulin quantification, engraftment efficiency, survival analysis, and histopathological assessment of lymphoid organs. Advanced analytical capabilities encompass next-generation sequencing, cytokine profiling, and functional immune assays. Rigorous quality control measures—such as genetic validation, health monitoring, and standardized operating procedures—ensure the reliability and reproducibility of all models and data outputs.
Partnering with Protheragen provides access to scientifically validated SCID animal models, expert technical support, and fully integrated preclinical research solutions. Our commitment to quality, scientific rigor, and client collaboration accelerates the path from discovery to clinical translation. Contact us today to discuss your SCID research needs and discover how our tailored in vivo modeling services can advance your therapeutic programs.
Make Order
Experimental Scheme
Implementation
Conclusion
